{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:45:25Z","timestamp":1767825925825,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T00:00:00Z","timestamp":1210032000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/sj.bjc.6604376","type":"journal-article","created":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T07:42:52Z","timestamp":1210059772000},"page":"1797-1802","source":"Crossref","is-referenced-by-count":25,"title":["Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus"],"prefix":"10.1038","volume":"98","author":[{"given":"J P","family":"Boni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Leister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,6]]},"reference":[{"key":"BF6604376_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909\u2013918","journal-title":"J Clin Oncol"},{"key":"BF6604376_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jps.10539","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM (2004) Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93: 364\u2013374","journal-title":"J Pharm Sci"},{"key":"BF6604376_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1177\/0091270007306957","volume":"47","author":"J Boni","year":"2007","unstructured":"Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L (2007) Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 47: 1430\u20131439","journal-title":"J Clin Pharmacol"},{"key":"BF6604376_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clpt.2004.08.025","volume":"77","author":"JP Boni","year":"2005","unstructured":"Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77: 76\u201389","journal-title":"Clin Pharmacol Ther"},{"key":"BF6604376_CR5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1124\/dmd.107.014746","volume":"35","author":"P Cai","year":"2007","unstructured":"Cai P, Tsao R, Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35: 1554\u20131563","journal-title":"Drug Metab Dispos"},{"key":"BF6604376_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De AL, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357\u2013361","journal-title":"Invest New Drugs"},{"key":"BF6604376_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic\u2013pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 41\u201357","journal-title":"Clin Pharmacokinet"},{"key":"BF6604376_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000094133","volume":"26","author":"KF El-Dahshan","year":"2006","unstructured":"El-Dahshan KF, Bakr MA, Donia AF, Badr A, Sobh MA (2006) Ketoconazole\u2013tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am J Nephrol 26: 293\u2013298","journal-title":"Am J Nephrol"},{"key":"BF6604376_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","volume":"24","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200\u2013216","journal-title":"Mol Cell Biol"},{"key":"BF6604376_CR10","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755\u20135763","journal-title":"Clin Cancer Res"},{"key":"BF6604376_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271\u20132281","journal-title":"N Engl J Med"},{"key":"BF6604376_CR12","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004\u20137014","journal-title":"Mol Cell Biol"},{"key":"BF6604376_CR13","first-page":"2.1","volume-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","author":"WJ Jusko","year":"1992","unstructured":"Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data. In Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Evans WE, Schentag JJ, Jusko WJ (eds) pp 2.1\u20132.43. Applied Therapeutics Inc: Vancouver, Wash"},{"key":"BF6604376_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0091270005275368","volume":"45","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45: 514\u2013518","journal-title":"J Clin Pharmacol"},{"key":"BF6604376_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/bdd.524","volume":"27","author":"JM Kovarik","year":"2006","unstructured":"Kovarik JM, Beyer D, Schmouder RL (2006) Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 27: 421\u2013426","journal-title":"Biopharm Drug Dispos"},{"key":"BF6604376_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0300-483X(95)03155-9","volume":"104","author":"AP Li","year":"1995","unstructured":"Li AP, Kaminski DL, Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104: 1\u20138","journal-title":"Toxicology"},{"key":"BF6604376_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/annonc\/mdg248","volume":"14","author":"CJ Punt","year":"2003","unstructured":"Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14: 931\u2013937","journal-title":"Ann Oncol"},{"key":"BF6604376_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253\u2013262","journal-title":"Cell"},{"key":"BF6604376_CR19","first-page":"414","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6604376_CR20","first-page":"3749S","volume":"7","author":"JS Skotnicki","year":"2001","unstructured":"Skotnicki JS, Leone CL, Smith AL, Palmer YL, Yu K, Discafani CM, Gibbons JJ, Frost P, Abou-Gharbia MA (2001) Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract 477]. Clin Cancer Res 7: 3749S\u20133750S","journal-title":"Clin Cancer Res"},{"key":"BF6604376_CR21","unstructured":"Torisel [package insert] (2007). Wyeth Pharmaceuticals Inc.: Philadelphia, PA"},{"key":"BF6604376_CR22","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1208\/aapsj060428","volume":"6","author":"JJ Zimmerman","year":"2004","unstructured":"Zimmerman JJ (2004) Exposure\u2013response relationships and drug interactions of sirolimus. AAPS J 6: e28","journal-title":"AAPS J"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604376","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:05Z","timestamp":1684413185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,6]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BF6604376"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604376","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,6]]}}}